EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of acute hepatic encephalopathy with rifaximin in comparison with lactitol A multi-centre, double-blind, double-dummy, randomized controlled trial



Treatment of acute hepatic encephalopathy with rifaximin in comparison with lactitol A multi-centre, double-blind, double-dummy, randomized controlled trial



Journal of Hepatology 30(SUPPL 1): 81




(PDF 0-2 workdays service: $29.90)

Accession: 035980758

Download citation: RISBibTeXText



Related references

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. Journal of Hepatology 38(1): 51-58, January, 2003

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. Journal of Hepatology 38(1): 51-58, 2002

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Current Medical Research and Opinion 13(2): 109-118, 1993

Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. European Journal of Gastroenterology & Hepatology 12(2): 203-208, 2000

Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 7(6): 1278-1284, 1987

Randomized controlled trial for the prevention of early post-TIPS hepatic encephalopathy Comparison between rifaximin, lactitol and no treatment. Hepatology 34(4 Pt 2): 549A, October, 2001

A multi-center, randomized, controlled, double blind and double dummy clinical trial of antofloxacin hydrochloride tablet versus levofloxacin tablet for the treatment of acute bacterial infections. Zhonghua Nei Ke Za Zhi 50(3): 225-229, 2011

Lactitol in treatment of subclinical hepatic encephalopathy A double-blind placebo-controlled randomised trial. Chinese Medical Journal (English Edition) 111(2): 135, 1998

Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial. Shanghai Archives of Psychiatry 27(4): 228-236, 2015

Comparison of a Chinese Herbal Medicine (CCH1) and Lactulose as First-Line Treatment of Constipation in Long-Term Care: A Randomized, Double-Blind, Double-Dummy, and Placebo-Controlled Trial. Evidence-Based Complementary and Alternative Medicine 2012: 923190-923190, 2012

Efficacy and Safety of FospropofolFD Compared to Propofol When Given During the Induction of General Anaesthesia: A Phase II, Multi-centre, Randomized, Parallel-Group, Active-Controlled, Double-Blind, Double-Dummy Study. Basic & Clinical Pharmacology & Toxicology 119(1): 93-100, 2016

Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial. Bmc Complementary and Alternative Medicine 16(): 356-356, 2016

Comparison of the efficacy, tolerability, and smoothness indexes of two nifedipine formulations: A randomized, double-dummy, double-blind, controlled trial. Current Therapeutic Research 63(5): 305-315, 2002

Re: Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial. Journal of Urology 188(4): 1236-1237, 2012

Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial. Clinical Therapeutics 33(12): 1943-1952, 2012